



DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL RP-HPLC METHOD FOR 
AZILSARTAN MEDOXOMIL WITH LIQUID-LIQUID EXTRACTION 
Original Article 
 
SNEHAL KARPE, SANDEEP SONAWANE*, PRIYA RAHADE, SANJAY KSHIRSAGAR 
MET’s Institute of Pharmacy, MET League of Colleges, Bhujbal Knowledge City, Adgaon, Nashik, Maharashtra, India 
Email: sandeeps.iop@gmail.com  
 Received: 13 Nov 2015 Revised and Accepted: 19 Dec 2015 
ABSTRACT 
Objective: There are many analytical methods available for estimation of Azilsartan medoxomil in biological samples and for pharmaceutical 
preparations. However, no specific RP-HPLC method with UV detection based on liquid-liquid extraction technique is available for estimation of 
Azilsartan medoxomil in human plasma.  
Methods: A simple, rapid and accurate RP-HPLC with UV detection method was developed and validated as per US-FDA guidelines for the 
estimation of Azilsartan medoxomil in spiked human plasma using liquid-liquid extraction technique.  
Results: Azilsartan medoxomil was well resolved from human plasma interference and internal standard (Aceclofenac) using C 18 (250 × 4.6 mm, 5 
μ) column with methanol: 20 mm phosphate buffer (pH 3.0), (70: 30 %, v/v) as mobile phase, at a flow rate of 1 ml/min. The detection was 
performed at 249 nm. The calibration curve was found linear in the range of 500-16000 ng/ml. During calibration experiments, the 
heteroscedasticity was minimized by using weighted least square regression model with weighing factor 1/x². In accuracy and precision studies, 
intra-day and inter-day, % relative error was found between±15 and % RSD was less than 15 %. Stability experiments indicated that the drug 
remained stable after three freeze-thaw cycles.  
Conclusion: A simple, rapid and accurate RP-HPLC method with UV detection was developed and validated for estimation of Azilsartan medoxomil 
based on liquid-liquid extraction technique. The developed method meets the requirements of US-FDA guidelines. Also the developed method does 
not require expensive chemicals and solvents and does not involve complex instrumentation, hence it is economic. 
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INTRODUCTION 
Azilsartan medoxomil chemically is (5–methyl–2–oxo-1,3–dioxol–4-
yl) methyl 2–ethoxy–3-[[4-[2- (5–oxo-2H-1, 2, 4–oxadiazol–3-yl) 
phenyl] phenyl] methyl] benzimidazole–4-carboxylate [1]. It is 












 receptor blocker [2]. The structure of Azilsartan 
is given in [fig. 1].  
 
Fig. 1: Structure of Azilsartan medoxomil 
 
Literature survey revealed few methods for quantitative analysis of 
Azilsartan medoxomil in biological samples and in pharmaceutical 
formulations alone as well as in combination with other drugs. 
These include RP-HPLC method with PDA detection in human 
plasma by solid-phase extraction procedure [3], UPLC with MS/MS 
in beagle dog plasma with its application to pharmacokinetic studies 
by protein precipitation method [4], HPTLC method [5], 
determination of potential impurities in tablets by UPLC with UV 
detection [6], UV spectrophotometric method for determination of 
Azilsartan medoxomil in bulk and pharmaceutical dosage form [7]. 
Also, quantification methods of Azilsartan medoxomil in 
combination with Chlorthalidone include, LC with electrospray 
ionization operated in negative multiple reaction monitoring (MRM) 
mode in rat and human plasma by liquid-liquid extraction method 
[8], stability-indicating RP-HPLC method with UV detection [9] and 
spectrophotometric method based on first derivative spectra and 
spectro fluorometric methods[10]. 
Most of the earlier methods are based on the use of sophisticated 
instruments like LC-MS, UPLC-MS, which are not available in routine 
quality control laboratories and academic institute laboratories. 
Therefore, the present work was undertaken with the objective of 
developing and validating a simple and rapid RP-HPLC with UV 
detection method for determination of Azilsartan medoxomil in 
human plasma based on liquid-liquid extraction technique which is 
cost effective and an efficient extraction technique. Also, the second 
objective of work was to suggest an approach in the selection of 
optimum calibration model.  
MATERIALS AND METHODS 
Materials and instrumentation 
Pharmaceutical grade Azilsartan medoxomil and Aceclofenac used 
as an internal standard were provided as ex-gratis from Glenmark 
Pharmaceuticals, Sinnar, Nashik, India and Blue Cross Laboratories 
Ltd., Ambad, Nashik, India, respectively. Blank human plasma was 
provided as a gift sample from Dr. Vasantrao Pawar Medical College, 
Hospital and Research Centre, Nashik, India. Blank plasma was 
pooled by thoroughly mixing the plasma obtained from six different 
sources. Methanol used in the analysis was of HPLC grade, and all 
other chemicals were of analytical reagent grade, purchased from SD 
Fine Chemicals, Mumbai, India. The Durapore, 0.45 µ × 47 mm, 
membrane filter papers were purchased from Millipore (India) Pvt. 
Ltd., Bengaluru, India. Freshly prepared double distilled water used 
in the analysis was prepared from Borosil All Glass Double 
Distillation Assembly, purchased from Borosil, Mumbai, India. 
Chromatographic analysis was carried out using an HPLC system 
consisting of pump PU-2080 Plus (JASCO Corporation, Tokyo, Japan) 
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equipped with 100 µl Rheodyne loop injector (7725i) and detection 
was carried out on UV-2075 detector (JASCO Corporation, Tokyo, 
Japan) using Borwin Chromatography software (Version 1.50). 
Preparation of standard stock solution and working standard 
solution for azilsartan medoxomil and aceclofenac 
The stock solution of (1 mg/ml) of Azilsartan medoxomil was 
prepared in methanol and was further appropriately diluted with 
methanol to get six different working standard solutions with 
concentration 5, 10, 20, 40, 80 and 160µg/ml. Similarly, the stock 
solution (10 mg/ml) of Aceclofenac was prepared in methanol and 
appropriately diluted with methanol to get working standard 
solution of 100 µg/ml. 
Preparation of calibration curve (CC) standards and quality 
control (QC) samples  
Aliquots of 200 µl of pooled blank plasma were taken in stoppered 
glass tubes of capacity 20 ml. To this, 25 µl of 25 µg/ml methanolic 
standard stock solution of Azilsartan medoxomil (2500 ng) was 
added and to each tube, 25 µl of working standard solution of 
Aceclofenac (as internal standard) was added. The resulting 
solutions were vortex mixed for 1 min to get CC standards 
containing 500, 1000, 2000, 4000, 8000 and 16000 ng/ml of 
Azilsartan, respectively. The QC samples were similarly prepared to 
contain three concentrations [1500 ng/ml Low-Quality Control 
(LQC), 8000 ng/ml Middle-Quality Control (MQC) and 16000ng/ml 
High-Quality Control (HQC)]. 
Liquid-liquid extraction (LLE) experiments  
Aliquots of pooled human plasma (200 µl) were taken in 20 ml 
stoppered glass test tubes. To each of these tubes 25 µl of 25 µg/ml 
methanolic solution of Azilsartan medoxomil and 25 µl of 100 µg/ml 
of working standard solution of Aceclofenac was added. To each 
tube, 3 ml of organic solvent was added, and the tubes were shaken 
in an inclined position on a reciprocating shaker at 100 strokes/min 
for 3 min. Further, these tubes were centrifuged at 3000 rpm for 10 
min. The separated organic layer from each tube was transferred to 
separate glass tube and evaporated to dryness under a stream of 
nitrogen. The residue obtained upon evaporation to dryness was 
reconstituted with 250 µl of mobile phase and 100 µl was injected 
into HPLC system under optimal chromatographic conditions. 
Chromatographic conditions  
Chromatographic analysis was carried out on a C 18Phenomenex 
Hyperclone column (250 × 4.6 mm, 5 µm) with mobile phase 
consisting of methanol: 20 mm potassium phosphate buffer (pH 3.0), 
(70:30 %, v/v) at a flow rate of 1 ml/min. The detection was carried 
out at 249 nm.  
Calibration runs  
In the calibration experiments, 200 µl aliquots of all CC standards 
were analyzed in six replicates using optimized LLE method and 
appropriate chromatographic conditions. All calibration curves (CC) 
were analyzed in six replicates. Prior to analysis, each CC standard 
was mixed with 25 µl of 100 µg/ml methanolic solution of 
Aceclofenac (as internal standard). At the end of the calibration runs, 
the chromatograms of CC standards were processed to get the peak 
areas for Azilsartan medoxomil and Aceclofenac. For each CC 
standard, the area ratio of Azilsartan medoxomil and Aceclofenac 
was calculated.  
Selection of calibration model and range  
Data obtained from the run calibration experiments was subjected 
to unweighted and weighted least square regression analysis to 
generate the respective calibration equations [11]. In weighted 
regression, weighting factors (w) of 1/x and 1/x2
In order to select the best calibration model, each calibration model 
and equation was evaluated with respect to % Relative error (%RE), 
Residual plot and homogeneity of variance (homoscedasticity) in the 
linear range [12].  
 were used, where x 
is the concentration of the CC standards of Azilsartan medoxomil.  
The area ratios for the CC standards were referred to the calibration 
equation to get the back-calculated concentrations (interpolated 
concentrations) for the each CC standards. The total % RE was 
calculated as the sum of % RE for all CC standards. 
The predicted area ratios for CC standards were calculated by 
entering the nominal concentration of each CC standard into the 
calibration equation. A plot of residuals was constructed by plotting 
the differences between measured and predicted area ratios against 
nominal log concentration, and the scatter of residual was evaluated.  
To evaluate homoscedasticity in the linear range, the variance of 
residuals at highest CC standard to the lowest CC standard was 
evaluated by means of one-way ANOVA.  
The calibration model with minimum % RE, random scatter of 
points in the plot of residuals and no significant difference in one-
way ANOVA was selected.  
Validation studies  
The developed method was validated as per US-FDA Guidance for 
Industry: Bioanalytical Method Validation (September 2013)[13]. 
Selectivity was studied at the lower limit of quantification (LLOQ) at 
500ng/ml by comparing blank responses of plasma from six 
different sources with peak areas afforded by LLOQ samples. The 
Calibration curve standards were evaluated by preparing and 
analyzing CC standard solutions spiked with an internal standard for 
five days. The concentrations of each CC standard were back 
calculated using suggested calibration model and the deviation of 
the back-calculated concentrations from nominal values was studied 
and expressed as % nominal.  
Precision and accuracy were studied by analyzing five bioanalytical 
batches over five days. Each batch consisted of one blank, all CC 
standards and five replicates of LQC, MQC and HQC samples. The 
calibration equation was determined for each batch from analysis of 
CC standards and was used to calculate the concentration of 
Azilsartan medoxomil in LQC, MQC and HQC samples. The within 
batch and between batch accuracy and precision was determined in 
terms of % RE and % RSD, respectively. 
Stability of Azilsartan medoxomil in plasma was evaluated under 
various conditions viz. freeze-thaw cycles, stability at–20 °C for 30 d 
and stability at room temperature for 6 h. The amount of Azilsartan 
medoxomil in stability samples was found out and the % nominal 
and % RSD of the determinations were calculated.  
RESULTS 
When Azilsartan medoxomil and Aceclofenac were subjected to 
chromatographic analysis in mobile phases of different strengths 
and compositions, it was found that mobile phase consisting of 
methanol: 20 mm potassium phosphate buffer (pH 3.0), (70:30 %, 
v/v) gave adequate retention at a flow rate of 1 ml/min. The 
wavelength at which detection was carried out was 249 nm. The 
retention time for Azilsartan medoxomil was 5.53 min and for 
Aceclofenac, it was 9.61 min. various organic solvents like n-hexane, 
dichloromethane, diethyl ether and tert-Butyl methyl ether were 
tried in which good recovery was obtained with tert-Butyl methyl 
ether. Also, when aliquots of blank plasma were extracted with tert-
Butyl methyl ether and chromatographed under mentioned 
chromatographic conditions, it was found that there were no 
significant interfering peaks at the retention times of Azilsartan 
medoxomil and Aceclofenac. Thus, it was concluded that tert-Butyl 
methyl ether could be further used as LLE solvent for Azilsartan 
medoxomil and Aceclofenac. The chromatogram of blank plasma 
extracted in tert-Butyl methyl ether is shown in [fig. 2(a)]and the 
chromatogram of Azilsartan medoxomil and Aceclofenac extracted 
in tert-Butyl methyl ether is shown in [fig. 2(b)]. The extraction 
recovery obtained for Azilsartan medoxomil and Aceclofenac was 
58.25 % and 60.25 %, respectively. 
During calibration experiments, when data obtained from [table 
1]was subjected to unweighted and weighted linear regression with 
weighting factors 1/x and 1/x2;unweighted regression resulted in 
the equation Y = 0.0002x + 0.01099 and with 1/x and 1/x2weights, 
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resulted in equation, Y = 0.0002x+0.0156 and Y = 0.0002x+0.0142, 
respectively. Each of the obtained linear regression equations was 
evaluated for % RE, random scatter and homoscedasticity for 
selection of appropriate calibration model [table 2]. From this, it was 
concluded that although all calibration equations gave random 
scatter residuals, the total % RE was minimal when weighted 
regression with weighting factor 1/x2 was applied. Further, when 
the Fcalculated values were compared with Ftabulated (α = 0.05), it 
became evident that a weighting factor of 1/x2 was suitable to 
homogenize the variance of the residuals. Thus, it was decided to 
adopt calibration model of weighted linear regression with weighing 
factor 1/x2
  
 in the calibration range of 500 to 16000 ng/ml of drug.  
 
Fig. 2(a): Chromatogram of blank plasma extracted in tert-Butyl methyl ether, 2(b): Chromatogram of Azilsartan medoxomil and 
Aceclofenac extracted in tert-Butyl methyl ether 
 
Table 1: Area ratios from calibration experiments 
CC Amount of drug in ng/ml Area ratio (mean±SD) (n=6) 
1 500 0.1190±0.013 
2 1000 0.2108±0.020 
3 2000 0.4498±0.037 
4 4000 0.8663±0.047 
5 8000 1.5918±0.154 
6 16000 3.3145±0.254 
 
Table 2: Results of evaluation of various calibration models 
Unweighted regression Weighted regression (1/x) Weighted regression (1/x2) 
∑% 
RE 
Nature of residuals 
plot 
F5,5 ∑% RE * 
value 










36.18 Random scatter 349.207 -3.796-
E 
Random scatter 0.341 -8E-13 Random scatter 0.003 
* F value calculated as ratio of variances at the extremes of the calibration range, ** F value calculated as ratio of variances of the weighted residuals 
 
During validation studies, it was found that the peak areas for the 
lower limit of quantification (LLOQ) samples were more than five 
times the blank responses obtained using six different plasma 
sources which concluded that the method was deemed to be 
selective for an LLOQ of600 ng/ml. From [table 3], it was 
concluded that % nominal values of the back-calculated 
concentrations of CC standards were between 97-107 %, which 
were in acceptable limits. 
 
Table 3: Standard curve parameters for Azilsartan medoxomil 
CC Nominal conc. (ng/ml)  Back calculated concentrations (ng/ml) Mean ±SD % R. S. D. % Accuracy 
1 2 3 4 5 6 
1 500 499 431.5 599 449 537.5 575.5 515.2 67.53 13.10 103.05 
2 1000 1037 927.5 876 848 1094 1062.5 974.2 103.6 10.64 97.42 
3 2000 2136 1926 1981 2249 2236 2395.5 2154 176.7 8.20 107.7 
4 4000 4326 3926 3991 4427 4499 4342.5 4251.9 236.5 5.56 106.2 
5 8000 8035.5 6926 9207 7659 8020.5 7426.2 7879.0 770.6 9.78 98.48 
6 16000 15926.5 15543.5 15927 16649 17170.6 18982 16699.8 1262.0 7.55 104.3 
 
The evaluation of accuracy and precision showed that the intra-day 
% RE was between±15 %, while the % RSD was less than 15 %. The 
US-FDA Guidelines require that % RE be between±15 %, while % 
RSD should be less than 15 %. The results of precision and accuracy, 
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as well as extraction recovery for Azilsartan medoxomil at LQC, MQC 
and HQC and for Aceclofenac, are presented in [table 4]. Further, the 
intermediate precision of the method was determined by using a 
one-way ANOVA. For each QC level, within mean square and between 
mean square values were determined. The total variance was taken 
as a sum of within and between mean squares and the standard 
deviation was determined as a square root of total variance and F 
value was determined. The Fcalculated was found less than Ftabulated
  
 (α = 
0.05), [table 5] indicates that there is no significant difference 
between intra-day and inter-day precision. 
Table 4: Results of accuracy and precision studies 
Intraday n= 5 Interday n = 5 
QC Level Conc in ng/ml Mean conc found ng/ml %RE %RSD Mean conc found ng/ml %RE %RSD % Recovery 
LQC 1500 1513.2 0.82 4.64 1563.32 5.27 5.15 41.08 
MQC 8000 8003.6 0.03 3.12 8378.5 4.70 4.99 58.4846 
HQC 16000 17366.5 8.54 2.9 16970.1 6.06 4.54 46.88 
IS - - - - - - - 60.25 
 
Table 5: Results of one-way ANOVA at each QC level 
QC Level Source Sum of squares Df Mean squares Total Variance ±SD F value 
LQC Within run 168784 20 8439.2 12435.4 111.5 3.8 
Between run 129666 4 32417 
MQC Within run 4586655 20 229333 3911007 625.3 5.2 
Between run 4799763 4 1199941 
HQC Within run 1.490Eto7 20 745214 1230856 1109.4 4.9 
Between run 1.463Eto7 4 3659064 
 
Table 6: Results of stability studies for Azilsartan medoxomil 
QC Level Stability at RT Stability at-20°C Freeze-thaw stability 
 %Nominal % RSD %Nominal % RSD %Nominal % RSD 
LQC 102.21 3.37 102.3 3.85 101.26 4.9 
HQC 101.73 3.22 100.6 5.66 100.23 6.92 
 
The results of stability evaluation of Azilsartan medoxomil are 
presented in [table 6]. Analysis cycles viz. three freeze-thaw cycles, 
stability at-20 °C for 30 d and stability at room temperature for 6 h 
indicated that Azilsartan medoxomil was stable in human plasma 
under these conditions. The developed method is sensitive and 
convenient for use. The developed method does not require 
expensive chemicals and solvents and does not involve complex 
instrumentation or sample preparation methods and hence it is 
simple and economical as compared to previously reported 
methods.  
CONCLUSION 
In this report, a simple, rapid, selective and accurate HPLC-UV 
method was described for the quantification of Azilsartan 
medoxomil in spiked human plasma using liquid-liquid extraction. 
The developed bioanalytical method is capable of quantifying 
Azilsartan medoxomil from spiked human plasma in the 
concentration range of 500–16000 ng/ml. The method meets the 
requirements of the US-FDA guidelines.  
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